Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company

Refine Search
Europe
The UK Intellectual Property Office has blocked Canadian brand Vivo Cannabis from registering ‘Lumina’ as a trademark, after an opposition from an Italian pharmaceutical company.   7 February 2020
Big Pharma
US multinational biotechnology company Biogen has successfully defended multiple sclerosis treatment Tecfidera from a patent challenge brought by generic and specialty pharma company Mylan.   6 February 2020
article
European patent attorney Dr. Thomas Wolter has joined the Munich office of European IP law firm Mewburn Ellis.   6 February 2020
Americas
Gilead has suffered a blow in its efforts to invalidate the US government’s patent rights for PrEP, as the Patent Trial and Appeal Board threw out two of its four patent challenges.   6 February 2020
Americas
A state-run institution in China has applied for a patent on the use of an experimental Gilead Sciences drug, which scientists believe may be able to fight the coronavirus outbreak that has killed hundreds.   6 February 2020
Americas
Bristol-Myers Squibb and BioMotiv, a drug development accelerator, have launched Anteros Pharmaceuticals, a biotech focused on developing a new class of drugs for fibrotic and other inflammatory diseases.   5 February 2020
Americas
US competition regulators will increase scrutiny of biologic and biosimilar-related patent settlements, as they look to crack down on antitrust violations.   4 February 2020
Americas
Pharmaceutical company Amgen has asked a full US Court of Appeals for the Federal Circuit to review the overturning of a record $2.5 billion verdict against Gilead Sciences.   4 February 2020
Biotechnology
The UK Intellectual Property Office and the Chartered Institute of Patent Attorneys have worked together to ensure changes are made to “misleading” advice issued by the EU’s Community Plant Variety Office.   3 February 2020
Big Pharma
The Court of Justice of the European Union has ruled that pharmaceutical pay-for-delay agreements may violate the Treaty on the Functioning of the European Union, in comments passed down on January 30, 2020.   31 January 2020